Who Paid My Doc
Maria Lepore
Registered Nurse, Ambulatory Care Wayne, PA Nurse Practitioner
NPI 1386970069 CMS profile 10484689
656 E Swedesford Rd, Wayne, PA 19087
General payments
$25
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Maria Lepore of Wayne, PA is reported in the CMS Open Payments database as having received $25 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $25 | 1 |
Beside peers
- Maria Lepore
- Registered Nurse, Ambulatory Care median
- Middle half of Registered Nurse, Ambulatory Care
- National median
In program year 2025, general payments to Maria Lepore were reported at $25. Among 38 Registered Nurse, Ambulatory Care profiles paid that year, the median was $69 and the middle half received between $26 and $142.
Show as a table
| Year | Maria Lepore | Registered Nurse, Ambulatory Care median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | — | — | $132 |
| 2022 | $0 | $31 | $23–$126 | $149 |
| 2023 | $0 | $125 | $41–$253 | $160 |
| 2024 | $0 | $111 | $29–$243 | $164 |
| 2025 | $25 | $69 | $26–$142 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 89 drugsPart D claims
2,685
Drug cost
$163,929
Branded share of claims
14.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Aptiom Eslicarbazepine Acetate | Brand | 21 | $26,282 | |
| Linzess Linaclotide | Brand | 20 | $11,208 | |
| Lacosamide | Generic | 29 | $9,099 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 12 | $8,175 | |
| Xarelto Rivaroxaban | Brand | 14 | $7,392 | |
| Myrbetriq Mirabegron | Brand | 17 | $6,534 | |
| Famotidine | Generic | 83 | $6,230 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 12 | $6,055 | |
| Ziprasidone Hcl | Generic | 38 | $5,107 | |
| Rosuvastatin Calcium | Generic | 113 | $4,755 |
The 10 drugs with the highest cost, of 89 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 476 Part D prescribers listed as Registered Nurse; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Registered Nurse, Ambulatory Care in Pennsylvania
Related records
Registered Nurse, Ambulatory Care in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Registered Nurse, Ambulatory Care
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.